In this week's PLOS Medicine, Ric Price and colleagues compare the burden of anemia in different plasmodia species in a robust hospital-based surveillance study in Eastern Indonesia.
Malaria transmission-blocking vaccines (TBVs) represent a promising approach for the elimination and eradication of this disease. AnAPN1 is a lead TBV candidate that targets a surface antigen on the midgut of the obligate vector of the Plasmodium parasite, the Anopheles mosquito. In this study, we demonstrate that antibodies targeting AnAPN1 block transmission of Plasmodium falciparum and Plasmodium vivax across distantly related anopheline species in malaria endemic countries.
The present study assessed the health system readiness to deploy RDTs and ACT for malaria control across the State.
We demonstrate that malaria patients display a significant reduction in circulating DC numbers and the concurrent accumulation of immature cells.
This study examines the influence of malaria status and altitude on haematologic parameters in school-aged pupils.
This study aims to compare the new VIKIA Malaria Ag Pf/PanTM RDT with PCR-corrected microscopy results and the commonly used CareStartTM RDT to diagnose falciparum and non-falciparum malaria in the endemic setting of Bamako, Mali and the non-endemic setting of Lyon, France.
The NLCR was found to correlate with parasitaemia, but both lymphocytopenia and the NLCR were inferior to C-reactive protein as markers for severe disease in patients with imported malaria
In areas of low malaria transmission, it is currently recommended that a single dose of primaquine (0.75 mg base/kg; 45 mg adult dose) be added to artemisinin combination treatment (ACT) in acute falciparum malaria to block malaria transmission.